Catalogo dei Corsi di studio

ANNA COPPA
Curriculum Vitae
Part I General Information
Full Name Anna Coppa
Date of Birth
Place of Birth
Citizenship
Permanent Address
Mobile Phone Number
E-mail anna.coppa@uniroma1.it
Spoken Languages Italiano-Inglese
Part II Education
Type Year Institution Notes (Degree, Experience, )
Titolo di Studio 1980 Università degli Studi Federico II Napoli Laurea in Medicina e Chirurgia
Titolo di Abilitazione 1981 Università degli Studi Federico II Napoli Abilitazione Esercizio della professione di
Medico Chirurgo
Specializzazione 1983 Università degli Studi Federico II Napoli Endocrinologia
Specializzazione 1987 Università degli Studi Federico II Napoli Patologia Generale
Titolo di Abilitazione 2018 ANVUR Abilitazione Scientifica Nazionale per
professore di II fascia SC06/A2- SSD
MED/04
Part III Appointments
IIIA Academic Appointments
Start End Institution Position
1990 1992 Dipartimento di Biologia e Patologia Cellulare e
Molecolare dell Università Federico II di Napoli
Collaboratore tecnico laureato
1992 2001 Dipartimento di Medicina Sperimentale Università
degli Studi Sapienza, Roma
Collaboratore tecnico laureato
2001 oggi Dipartimento di Medicina Sperimentale Università
degli Studi Sapienza, Roma
Ricercatore confermato
2008 2011 Facoltà di Medicina e Odontoiatria, Università degli
Studi Sapienza, Roma
Membro della Commissione Percorso Qualità
2011 oggi Facoltà di Medicina e Odontoiatria, Università degli
Studi Sapienza, Roma CCLTNPEE
Membro della Commissione Percorso Qualità
2008 2015 Dipartimento di Medicina Sperimentale Università
degli Studi Sapienza, Roma
Membro della Giunta di Dipartimento
Start End Institution Position
1990 1992 S.S. di Diagnostica Endocrinologica di
Laboratorio dUniversità Federico II Napoli
Dirigente medico di primo livello a tempo pieno
1992 2000 Servizio di Immunopatolgia Dipartimento di
Medicina Sperimentale, Università Sapienza
Roma
Dirigente medico di primo livello
2000 2005 Servizio di Collagenopatie Prev. Tratt. Amb.
Malattie Reumatiche Dipartimento di Medicina
Sperimentale, Università Sapienza Roma.
Dirigente medico di primo livello
2005 oggi UOSD Oncologia Molecolare, DAI Medicina
Diagnostica e Radiologia, AOU-Policlinico
Umberto I Roma
Dirigente medico di primo livello
2.1.2012 30.9.2012 Hilmann Cancer Center University of Pittsburg,
DNA Repair Laboratory
Visiting Scholar
1.7.1997 31.8.1997 Department of Anatomy and Cell Biology,
University of Toronto
Medical Visiting fellow
1.8.1995 30.11.1995 National Institute of Diabetes and Digestive and
Kidney (NIDDK), NIH Bethesda
Special volunteer
Part IV Teaching experience
Year Institution Lecture/Course
2000 ad
oggi
CLM B Facoltà di Medicina e Odontoiatria
Università degli Studi Sapienza, Roma
Patologia e Fisiopatologia Generale I e II
2000 ad
oggi
TPNEE Facoltà di Medicina e Odontoiatria
Università degli Studi Sapienza Roma
Patologia Generale e Fisiopatologia
2011 ad
oggi
Facoltà di Medicina e Odontoiatria dell Università
degli Studi Sapienza, Roma
Tutor per gli studenti del CLMB
2014-15 Università degli Studi Sapienza, Roma Docente del Dottorato in Medicina Molecolare
Part V - Society memberberships, Awards and Honors
Year Title
2002 ad
oggi
Membro della Società Italiana di Cancerologia (SIC)
2002 ad
oggi
Membro della Società European Association for Cancer Research (EACR)
2006-12 Membro della Società Italiana per la Biomedicina e Biotecnologie Spaziali (ISSBB)
Part VI - Funding Information [grants as PI-principal investigator or I-investigator]
Ultimi 10 anni
Year Title Program
2021-23 Dissecting new functions of the Nijmegen
breakage syndrome gene in cerebellar
development
Telethon Grant 2020
2021-25 Dissecting unconventional replication stress
responses to unravel new vulnerabilities of
MYCN-driven tumors
AIRC Investigator Grant 2020
2020 Analysis of Tumor Mutational Burden in Male
Breast Cancers characterized for germline
mutations in homologous recombination genes
Progetti medi dell'Università degli Studi
Sapienza
2019 New players in the Homologous Recombination
pathway: investigating the role of SMYD3 in
breast cancers characterized for BRCA mutation
status
Progetti medi dell'Università degli Studi
Sapienza
2018-20 Harnessing replication stress to understand and
tackle MYCN-dependent tumors
Istituto Pasteur Fondazione Cenci
Bolognetti Programmi di Ricerca Anna
Tramontano
2018 Providing insights into the transcriptome profile
of BRCA mutation-positive and -negative male
breast cancer
Progetti medi dell'Università degli Studi
Sapienza
2017 Exploring the transcriptional landscape of
BRCA-positive and BRCA-negative male breast
cancers by RNA-sequencing
Progetti medi dell'Università degli Studi
Sapienza
2016 Genomic screening of BRCA1/2 mutation
negative Italian male breast cancers by genepanel
sequencing
Progetti medi dell'Università degli Studi
Sapienza
2016-19 The MRN complex and PARP: targeting the
replication stress response in MYCN dependent
neuronal tumors
AIRC Investigator Grant 2015
2015-17 Insights into the functions of DNA damage
processing and repair factors to design novel
selective anticancer drugs
MIUR-PRIN 2015
2015 Applicazione del Next Generation Sequencing
(NGS) per l identificazione di alterazioni
genetiche nei tumori ereditari"
Progetti piccoli dell'Università degli
Studi Sapienza
2014-15 Uncovering the functional links between MYCN
and the MRN complex to understand the
phenotypic overlap between Nijmegen Breakage
syndrome and Feingold syndrome
Progetti di Ateneo dell'Università degli
Studi Sapienza
2013 Storia molecolare delle neoplasie:
caratterizzazione delle alterazioni genetiche ed
epigenetiche attraverso Next Generation
Sequencing
Progetti di Ateneo dell'Università degli
Studi Sapienza
2012 Development of new therapeutic strategies based
on cancer proteomics analysis of signal
transduction pathways important in brain tumor
stem cells
Progetti di Ateneo dell'Università degli
Studi Sapienza
2010-11 Hedgehog signaling regulatory networks in brain
cancer stem cells
Progetti di Ateneo dell'Università degli
Studi Sapienza
2009-11 Molecular Control of circadian rythms during
space flight (MOCC)
Biotechnology for human space
exploration (ASI)
Part VII Research Activities
Keywords Brief Description
NGS, Lung ca., Colon ca,
Multiple primary lung
cancers, Precision medicine
1) Nuovi approcci tecnologici nel campo dell oncologia molecolare: il next generation sequencing
nella diagnostica dei tumori ereditari e dei tumori solidi
2) Genetica molecolare delle neoplasie della mammella, ovaio e dei tumori della mammella maschile
3) Ruolo del DNA damage response nella cancerogenesi
4) Peroxiredoxine e ritmo circadiano; peroxiredoxine e cancro della tiroidea
5) Fisiopatologia della crescita e sopravvivenza delle cellule tiroide: ruolo del TGF-beta e della sua
via di segnale
6) Ruolo delle alterazioni di K-Ras, della PI3K nel controllo del potenziale invasivo di cellule
trasformate (mammella, tiroide).
BRCA, breast ca, ovarian
ca, VUS, splice variant,
male breast cancer,
transcriptome profiling,
molecular subtypes, breast
cancer susceptibility
DNA damage response,
MYCN, neuroblastoma,
PARP expression, PARP
inhibitors
PRDX2, Circadian rythm,
metabolic clock; PRDX1,
PRDX6, BRAF V600E,
papillary thyroid ca
FRTL5, cell growth, TGFb,
TGFb receptors, SMAD2,
SMAD4
Thyroid ca, PI3K, signal
transduction, KRAS, Cell
migration, motility and/or
invasion, EMT
Part VIII Summary of Scientific Achievements
Product type Number Data Base Start End
Papers [international] 46 SCOPUS 1995 2021
Papers [international] 40 WOS Author ID: N-3274-2016 1995 2021
SCOPUS WOS
Total Impact factor 188,306 188,306
Average Impact factor per product 4,09 4,09
Total Citations 798 695
Average Citations per Product 17,34 17,37
Average Citations per year 30,69 26,7
Hirsch (H) index 18 18
Normalized H index* 0,69 0,69
*H index divided by the academic seniority.
Part IX Selected Publications
1. Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti, Nicolis di Robilant V, Ramponi V, ScafettaV, Moretti M, Licursi
V, Belardinilli F, Peruzzi G, Infante P, Goffredo BM, Coppa A, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G and
Petroni M. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene 2021;
doi.org/10.1038/s41388-021-02003-0. PMID: 34508175
[WOS] Journal Impact Factor 2020: 9,867
2. Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis
IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J,
Berthet P, Boonen SE, Borg Å, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo
MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM; GEMO Study Collaborators; EMBRACE
Collaborators, Cook J, Coppa A, Cortesi L, Damante G .et al. Breast and Prostate Cancer Risks for Male BRCA1 and
BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst. 2021 Jul 28:djab147. doi:
10.1093/jnci/djab147. Online ahead of print
[WOS] Journal Impact Factor 2021: 13,5
3. Belardinilli F, Capalbo C, Malapelle U, Pisapia P, Raimondo D, Milanetti E, Yasaman M, Liccardi C, Paci P, Sibilio P, Pepe
F, Bonfiglio C, Mezi S, Magri V, Coppa A, Nicolussi A, Gradilone A, Petroni M, Di Giulio S, Fabretti F, Infante P, Coni S,
Canettieri G, Troncone G, Giannini G. Clinical multigene panel sequencing identifies distinct mutational association patterns
in metastatic colorectal. Front Oncol. 2020 May 7;10:560. doi: 10.3389/fonc.2020.00560. PMID: 32457828.
[WOS] Journal Impact Factor 2020: 6,24
4. Nicolussi A, Belardinilli F, Silvestri V, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S,
Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, Coppa A*, Capalbo C*. Identification of novel BRCA1 large genomic
rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data. Peer J. 2019 Nov
15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019. PMID: 31741787.
*corresponding authors
[WOS] Journal Impact Factor 2019: 2,379
5. Nicolussi A, Belardinilli F, Mahdavian Y. Colicchia V, D Inzeo S, Petroni M, Zani M. Ferraro S, Valentini V, Ottini L,
Giannini G. Capalbo C and Coppa A. Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of
germline mutations in hereditary breast/ovarian cancer Peer J. 7 (2019): e6661 DOI 10.7717/peerj.6661 PMID: 31065452
[WOS] Journal Impact Factor 2019: 2,379
6. Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa
A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V,
Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. A Simplified Genomic
Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers (Basel). 2019 Jan 27;11(2). pii: E147. doi:
10.3390/cancers11020147. PMID: 30691222
[WOS] Journal Impact Factor 2019: 6,126
7. Coppa A, Nicolussi A, D'Inzeo S, Capalbo C, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone
A, Bartolazzi A, Screpanti I, Ottini L, Giannini G. Optimizing the identification of risk-relevant mutations by multigene panel
testing in selected hereditary breast/ovarian cancer families. Cancer Med. 2017 Dec 22. doi: 10.1002/cam4.1251. [Epub
ahead of print] PMID: 29271107
[WOS] Journal Impact Factor 2017: 3,202
8. Coppa A, Buffone A, Capalbo C, Nicolussi A, D'Inzeo S, Belardinilli F, Colicchia V, Petroni M, Granato T, Midulla C, Zani
M, Ferraro S, Screpanti I, Gulino A, Giannini G. Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer
families widen the ovarian cancer cluster region boundaries to exons 13 and 14. Breast Cancer Res Treat. 2014
Dec;148(3):629-35. doi: 10.1007/s10549-014-3196-z. Epub 2014 Nov 14 PMID: 25395318.
[WOS] Journal Impact Factor 2014: 3,940
9. Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi
F, Giannini G, Coppa A. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and
-independent mechanisms. Int J Oncol. 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5. PMID:
24316730.
[WOS] Journal Impact Factor 2014: 3,025
10. D'Inzeo S, Nicolussi A, Donini CF, Zani M, Mancini P, Nardi F, Coppa A. A novel human Smad4 mutation is involved in
papillary thyroid carcinoma progression. Endocr Relat Cancer. 2012 2012 Jan 9;19(1):39-55. doi: 10.1530/ERC-11-0233.
Print 2012 Feb. PMID: 22109972.
[WOS] Journal Impact Factor 2012: 5,261
11. D'Inzeo S, Nicolussi A, Ricci A, Mancini P, Porcellini A, Nardi F, Coppa A. Role of reduced expression of SMAD4 in
papillary thyroid carcinoma. J Mol Endocrinol. 2010 Oct;45(4):229-44. doi: 10.1677/JME-10-0044. PMID: 20685810
[WOS] Journal Impact Factor 2010: 3
12. Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Costantini R, Gulino A, Coppa A. A complex pattern of
mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene 2005 Aug 11;24(34):5344-54 doi:
10.1038/sj.onc.1208603. PMID: 15940269.
[WOS] Journal Impact Factor 2005: 6,
All publication
Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti , Nicolis di Robilant V, Ramponi V, ScafettaV, Moretti M, Licursi
V, Belardinilli F, Peruzzi G, Infante P, Goffredo BM, Coppa A, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G and
Petroni M. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene 2021;
doi.org/10.1038/s41388-021-02003-0. PMID: 34508175
[WOS] Journal Impact Factor 2020: 9,867
Zelli V, Silvestri V, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D,
Tibiletti MG, Fox SB, Fab K, Palli D, Ottini L Transcriptome of Male Breast Cancer Matched with Germline Profiling
Reveals Novel Molecular Subtypes with Possible Clinical Relevance. Cancers (Basel). 2021 Sep 8;13(18):4515.
doi:10.3390/cancers13184515. PMID:34572741
[WOS] Journal Impact Factor 2021: 6,639
Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K,
Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M,
Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés
T, Caligo MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM; GEMO Study Collaborators;
EMBRACE Collaborators, Cook J, Coppa A, Cortesi L, Damante G .et al. Breast and Prostate Cancer Risks for Male
BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst. 2021 Jul 28:djab147.
doi: 10.1093/jnci/djab147. Online ahead of print
[WOS] Journal Impact Factor 2021: 13,5
Belardinilli F, Pernazza A, Mahdavian Y, Cerbelli B, Bassi M, Gradilone A, Coppa A, Pignataro MG, Anile M, Venuta F,
Della Rocca C, Giannini G, d'Amati G. A multidisciplinary approach for the differential diagnosis between multiple primary
lung adenocarcinomas and intrapulmonary metastases. Pathol Res Pract. 2021 Apr;220:153387. doi:
10.1016/j.prp.2021.153387.
[WOS] Journal Impact Factor 2021: 3,250
Nicolussi A, Belardinilli F, Ottini L, Petroni M, Capalbo C, Giannini G, Coppa A. A novel BRCA2 splice variant identified
in a young woman. Mol Genet Genomic Med. 2020 Dec;8(12):e1513. doi: 10.1002/mgg3.1513 PMID:33159495 DOI:
10.1002/mgg3.1513
[WOS] Journal Impact Factor 2020: 2.
Pecorella I, Coppa A, Nicolussi A, Manganaro L, Fiorentin F, Palaia I, Muzii L. CTNNB1 p.L31P mutation in an ovarian
endometrioid carcinoma with synchronous uterine endometrioid carcinoma Pathol Res Pract. 2020 Oct 18;216(12):153260.
doi: 10.1016/j.prp.2020.153260. PMID: 33120166.
[WOS] Journal Impact Factor 2020: 3,250
Belardinilli F, Capalbo C, Malapelle U, Pisapia P, Raimondo D, Milanetti E, Yasaman M, Liccardi C, Paci P, Sibilio P, Pepe
F, Bonfiglio C, Mezi S, Magri V, Coppa A, Nicolussi A, Gradilone A, Petroni M, Di Giulio S, Fabretti F, Infante P, Coni S,
Canettieri G, Troncone G, Giannini G. Clinical multigene panel sequencing identifies distinct mutational association patterns
in metastatic colorectal. Front Oncol. 2020 May 7;10:560. doi: 10.3389/fonc.2020.00560. PMID: 32457828. Selezionato
[WOS] Journal Impact Factor 2020: 6,24
Petroni M, Sahùn Roncero M, Ramponi V, Fabretti F, Nicolis Di Robilant V, Moretti M, Alfano V, Corsi A, De Panfilis S,
Giubettini M, Di Giulio S, Capalbo C, Belardinilli F, Coppa A, Sardina F, Colicchia V, Pedretti F, Infante P, Cardinali B,
Tessitore A, Canettieri G, De Smaele E, Giannini G. SMO-M2 mutation does not support cell-autonomous Hedgehog activity
in cerebellar granule cell precursors. Sci Rep. 2019 Dec 23;9(1):19623. doi: 10.1038/s41598-019-56057-y. PMID:
31873117.
[WOS] Journal Impact Factor 2019: 3,998
Nicolussi A, Belardinilli F, Silvestri V, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S,
Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, Coppa A, Capalbo C. Identification of novel BRCA1 large genomic
rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data. Peer J. 2019 Nov
15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019. PMID: 31741787.
[WOS] Journal Impact Factor 2019: 2,379
Rizzolo P, Silvestri V, Valentini V, Zelli V, Bucalo A, Zanna I, Bianchi S, Tibiletti MG, Russo A, Varesco L, Tedaldi G,
Bonanni B, Azzollini J, Manoukian S, Coppa A, Giannini G, Cortesi L, Viel A, Montagna M, Peterlongo P, Radice P, Palli
D, Ottini L. Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. Endocr Connect. 2019 Jul 1.
pii: EC-19-0225.R1. doi: 10.1530/EC-19-0225. [Epub ahead of print] PMID: 31336362.
[WOS] Journal Impact Factor 2019: 2,592
Nicolussi A, Belardinilli F, Mahdavian Y. Colicchia V, D Inzeo S, Petroni M, Zani M. Ferraro S, Valentini V, Ottini L,
Giannini G. Capalbo C and Coppa A. Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of
germline mutations in hereditary breast/ovarian cancer Peer J. 7 (2019): e6661 DOI 10.7717/peerj.6661 PMID: 31065452
[WOS] Journal Impact Factor 2019: 2,379
Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa
A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V,
Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. A Simplified Genomic
Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers (Basel). 2019 Jan 27;11(2). pii: E147. doi:
10.3390/cancers11020147. PMID: 30691222
[WOS] Journal Impact Factor 2019: 6,126
Capalbo C, Belardinilli F, Filetti M, Parisi C, Petroni M, Colicchia V, Tessitore A, Santoni M, Coppa A, Giannini G,
Marchetti P. Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway
inhibition. Mol Clin Oncol. 2018 Jul;9(1):30-34. doi: 10.3892/mco.2018.1634. PMID: 29977536
[WOS] Journal Impact Factor 2018: 0,5 citations
Belardinilli F, Gradilone A, Gelibter A, Zani M, Occhipinti M, Ferraro S, Nicolazzo C, Coppa A, Giannini G. Coexistence
of three EGFR mutations in an NSCLC patient: A brief report. Int J Biol Markers. 2018 Jun
doi:10.1177/1724600818782200 PMID: 29945477 29977536
[WOS] Journal Impact Factor 2018: 1,767
Petroni M, Sardina F, Infante P, Bartolazzi A, Locatelli E, Fabretti F, Di Giulio S, Capalbo C, Cardinali B, Coppa A,
Tessitore A, Colicchia V, Sahùn Roncero M, Belardinilli F, Di Marcotullio L, Soddu S, Comes Franchini M, Petricci E,
Gulino A, Giannini G. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Cell Death Dis. 2018 Aug 30;9(9):895. doi: 10.1038/s41419-018-0924-z. PMID: 30166519
[WOS] Journal Impact Factor 2018: 5,959
Rizzolo P, Silvestri V, Bucalo A, Zelli V, Valentini V, Catucci I, Zanna I, Masala G, Bianchi S, Spinelli AM, Tommasi S,
Tibiletti MG, Russo A, Varesco A, Coppa A, Calistri D, Cortesi L, Viel V, Bonanni B, Azzollini J, Manoukian S, Montagna
M, Radice P, Palli D, Peterlongo P and Ottini L. Contribution of MUTYH variants to male breast cancer risk: results from a
multicenter study in Italy. Frontiers in Oncology. 4 December 2018 doi: 10.3389/fonc.2018.00583 PMID: 30564557
[WOS] Journal Impact Factor 2018: 4,137
Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A,
Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L.
A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. Breast.
2017 Dec 26;38:92-97. doi: 10.1016/j.breast.2017.12.013 PMID: 29287190.
[WOS] Journal Impact Factor 2017: 2,951
Coppa A, Nicolussi A, D'Inzeo S, Capalbo C, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone
A, Bartolazzi A, Screpanti I, Ottini L, Giannini G. Optimizing the identification of risk-relevant mutations by multigene panel
testing in selected hereditary breast/ovarian cancer families. Cancer Med. 2017 Dec 22. doi: 10.1002/cam4.1251. [Epub
ahead of print] PMID: 29271107
[WOS] Journal Impact Factor 2017: 3,202
Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli
F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G. PARP inhibitors enhance replication stress and cause
mitotic catastrophe in MYCN-dependent neuroblastoma. Oncogene 2017 Apr 10. doi: 10.1038/onc.2017.40. [Epub ahead of
print] PMID: 28394338
[WOS] Journal Impact Factor 2017: 6,854
Nicolussi A, D'Inzeo S, Capalbo C, Giannini G, Coppa A. The role of peroxiredoxins in cancer. Mol Clin Oncol. 2017
Feb;6(2):139-153. doi: 10.3892/mco.2017.1129 Epub 2017 Jan 10. PMID: 28357082
[WOS] Journal Impact Factor 2017: 0,5
Silvestri V, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, Agata S, Oliani C, Barana D, Castrignanò T, Viel A,
Russo A, Tibiletti MG, Zanna I, Masala G, Cortesi L, Manoukian S, Azzollini J, Peissel B, Bonanni B, Peterlongo P, Radice
P, Palli D, Giannini G, Chillemi G, Montagna M, Ottini L. Whole-exome sequencing and targeted gene sequencing provide
insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer 2016 Sep 20. doi: 10.1002/cncr.30337.
[Epub ahead of print] PMID: 27648926.
[WOS] Journal Impact Factor 2016: 6,
Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, Coppa A,
Sciacchitano S, Giordano C, Pinnarò P, Sanguineti G, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado
G, Vizza E, Giannini G, Soddu S. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in
BRCA1/2-negative patients with early-onset breast cancer. J Exp Clin Cancer Res. 2016 Sep 6;35(1):135.
[WOS] Journal Impact Factor 2016: 5,89
Belardinilli F, Capalbo C, Buffone A, Petroni M, Colicchia V, Ferraro S, Zani M, Nicolussi A, D'Inzeo S, Coppa A, Screpanti
I, Gulino A, Giannini G. Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of
colorectal cancer. Clin Biochem. 2015 Sep;48(13-14):908-10. doi: 10.1016/j.clinbiochem.2015.04.003. Epub 2015 Apr 11
PMID: 25872148.
[WOS] Journal Impact Factor 2015: 2,382
Coppa A, Buffone A, Capalbo C, Nicolussi A, D'Inzeo S, Belardinilli F, Colicchia V, Petroni M, Granato T, Midulla C, Zani
M, Ferraro S, Screpanti I, Gulino A, Giannini G. Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer
families widen the ovarian cancer cluster region boundaries to exons 13 and 14. Breast Cancer Res Treat. 2014
Dec;148(3):629-35. doi: 10.1007/s10549-014-3196-z. Epub 2014 Nov 14 PMID: 25395318.
[WOS] Journal Impact Factor 2014: 3,940
Avitabile D, Ranieri D, Nicolussi A, D'Inzeo S, Capriotti AL, Genovese L, Proietti S, Cucina A, Coppa A, Samperi R,
Bizzarri M, Laganà A, Torrisi MR. Peroxiredoxin 2 nuclear levels are regulated by circadian clock synchronization in human
keratinocytes. Int J Biochem Cell Biol. 2014 Aug;53:24-34. doi: 10.1016/j.biocel.2014.04.024. Epub 2014 May 9 PMID:
24814289.
[WOS] Journal Impact Factor 2014: 4,046
Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi
E, Giannini G, Gulino A. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic
colorectal cancer: a case report. Cancer Biol Ther. 2014 Jul;15(7):826-31. doi: 10.4161/cbt.28878. Epub 2014 Apr 22
PMID: 24755613.
[WOS] Journal Impact Factor 2014: 3,072
Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi
F, Giannini G, Coppa A. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent
and -independent mechanisms. Int J Oncol. 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5. PMID:
24316730.
[WOS] Journal Impact Factor 2014: 3,025
D'Inzeo S, Nicolussi A, Nardi F, Coppa A. Effects of the Smad4 C324Y mutation on thyroid cell proliferation. Int J Oncol.
2013 Jun;42(6):1890-6. doi: 10.3892/ijo.2013.1908. Epub 2013 Apr 17 PMID: 23591524.
[WOS] Journal Impact Factor 2013: 2,773
Donini CF, Di Zazzo E, Zuchegna C, Di Domenico M, D'Inzeo S, Nicolussi A, Avvedimento EV, Coppa A, Porcellini A.
The p85 regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and
migration. Int J Oncol. 2012 May;40(5):1627-35. doi: 10.3892/ijo.2012.1383. Epub 2012 Feb 21 PMID: 22366926.
[WOS] Journal Impact Factor 2012: 2,657
D'Inzeo S, Nicolussi A, Donini CF, Zani M, Mancini P, Nardi F, Coppa A. A novel human Smad4 mutation is involved in
papillary thyroid carcinoma progression. Endocr Relat Cancer. 2012 2012 Jan 9;19(1):39-55. doi: 10.1530/ERC-11-0233.
Print 2012 Feb. PMID: 22109972.
[WOS] Journal Impact Factor 2012: 5,261
Anastasi E, Granato T, Coppa A, Manganaro L, Giannini G, Comploj S, Frati L, Midulla C. HE4 in the Differential Diagnosis
of a Pelvic Mass: A Case Report. Int J Mol Sci. 2011; Jan 18;12(1):627-32. doi: 10.3390/ijms12010627 PMID: 21340004.
[WOS] Journal Impact Factor 2011: 2,598
Mincione G, Di Marcantonio MC, Tarantelli C, D'Inzeo S, Nicolussi A, Nardi F, Donini CF, Coppa A. EGF and TGF- 1
Effects on Thyroid Function. J Thyroid Res. 2011; 2011:431718. doi: 10.4061/2011/431718. Epub 2011 Jun 13 PMID:
21760980.
[WOS] Journal Impact Factor 2011: 1,78
D'Inzeo S, Nicolussi A, Ricci A, Mancini P, Porcellini A, Nardi F, Coppa A. Role of reduced expression of SMAD4 in
papillary thyroid carcinoma. J Mol Endocrinol. 2010 Oct;45(4):229-44. doi: 10.1677/JME-10-0044. PMID: 20685810
[WOS] Journal Impact Factor 2010: 3,628
Picarelli A, Sabbatella L, Di Tola M, Silano M, Nicolussi A, D'Inzeo S, Coppa A. Nuclear fluorescence serum reactivity on
monkey oesophagus: a new antibody for the follow-up of coeliac disease? Clin Exp Immunol. 2010 Sep;161(3):417-25 doi:
10.1111/j.1365-2249.2010.04184.x PMID: 20529089.
[WOS] Journal Impact Factor 2010: 3,134
De Gregorio G, Coppa A, Cosentino C, Ucci S, Messina S, Nicolussi A, D'Inzeo S, Di Pardo A, Avvedimento EV, Porcellini
A. The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals. Oncogene. 2007 Mar
29;26(14):2039-47 doi: 10.1038/sj.onc.1210011 PMID: 17043656.
[WOS] Journal Impact Factor 2007: 6,44
Nicolussi A, D'Inzeo S, Gismondi A, Coppa A. Reduction of invasive potential in K-ras-transformed thyroid cells by
restoring of TGF-beta pathway. Clin Exp Metastasis. 2006;23(5-6):237-48 doi: 10.1007/s10585-006-9023-0 PMID:
17086361.
[WOS] Journal Impact Factor 2006: 1,986
Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Costantini R, Gulino A, Coppa A. A complex pattern of
mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene 2005 Aug 11;24(34):5344-54 doi:
10.1038/sj.onc.1208603. PMID: 15940269.
[WOS] Journal Impact Factor 2005: 6,872
Nicolussi A, D'Inzeo S, Santulli M, Colletta G, Coppa A. TGF-beta control of rat thyroid follicular cells differentiation.
Mol Cell Endocrinol. 2003 Sep 30;207(1-2): 1-11. doi: 10.1016/s0303-7207(03)00238-7 PMID: 12972178.
[WOS] Journal Impact Factor 2003: 2,637
Napolitano G, Montani V, Giuliani C, Di Vincenzo S, Bucci I, Todisco V, Laglia G, Coppa A, Singer DS, Nakazato M,
Kohn LD, Colletta G, Monaco F. Transforming growth factor-beta1 down-regulation of major histocompatibility complex
class I in thyrocytes: coordinate regulation of two separate elements by thyroid-specific as well as ubiquitous transcription
factors. Endocrinology 2000 Apr;14(4):486-505. doi: 10.1210/mend.14.4.0454 PMID: 10770487.
[WOS] Journal Impact Factor 2000: 4,79
Turco A, Scarpa S, Coppa A, Baccheschi G, Palumbo C, Leonetti C, Zupi G, Colletta G. Increased TGFbeta type II receptor
expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells. Exp Cell Res.
2000 Feb 25;255(1):77-85 doi: 10.1006/excr.1999.4750 PMID: 10666336.
[WOS] Journal Impact Factor 2000: 3,860
Baccante G, Mincione G, Di Febbo C, Coppa A, Angelucci D, Lapenna D, Cuccurullo F, Colletta G, Porreca E. Increased
type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge. Atherosclerosis 2000
Sep;152(1):51-7 doi: 10.1016/s0021-9150(99)00449-9 PMID: 10996339.
[WOS] Journal Impact Factor 2000: 3,386
Turco A, Coppa A, Aloe S, Baccheschi G, Morrone S, Zupi G, Colletta G. Overexpression of transforming growth factor
beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells. Int J Cancer. 1999
Jan 5;80(1):85-91 doi: 10.1002/(sici)1097-0215(19990105)80:13.0.co;2-p PMID: 9935236.
[WOS] Journal Impact Factor 1998: 3,545
Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR. Transforming growth factorbeta1
enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J
Cancer. 1998 Mar 2;75(5):721-30 doi: 10.1002/(sici)1097-0215(19980302)75:53.0.co;2-9.
[WOS] Journal Impact Factor 1998: 3,283
Lazzereschi D, Mincione G, Coppa A, Ranieri A, Turco A, Baccheschi G, Pelicano S, Colletta G. Oncogenes and
antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Cancer Res. 1997 Sep;16(3):325-32. PMID: 9387909.
[WOS] Journal Impact Factor 1997: 0,232
Lazzereschi D, Coppa A, Minicione G, Lavitrano M, Fragomele F, Colletta G. The phosphatase inhibitor okadaic acid
stimulates the TSH-induced G1-S phase transition in thyroid cells. Exp Cell Res. 1997 Aug 1;234(2):425-33. doi:
10.1006/excr.1997.3627 PMID: 9260913.
[WOS] Journal Impact Factor 1997: 3,056
Coppa A, Mincione G, Lazzereschi D, Ranieri A, Turco A, Lucignano B, Scarpa S, Ragano-Caracciolo M, Colletta G.
Restored expression of transforming growth factor beta type II receptor in k-ras-transformed thyroid cells, TGF betaresistant,
reverts their malignant phenotype. J Cell Physiol. 1997 Aug;172(2):200-8 doi: 10.1002/(SICI)1097-
4652(199708)172:23.0.CO;2-S PMID: 9258341
[WOS] Journal Impact Factor 1997: 2,458
Scarpa S, Coppa A, Ragano-Caracciolo M, Mincione G, Giuffrida A, Modesti A, Colletta G. Transforming growth factor
beta regulates differentiation and proliferation of human neuroblastoma. Exp Cell Res. 1996 Nov 25;229(1):147-54 doi:
10.1006/excr.1996.0352 PMID: 8940258
[WOS] Journal Impact Factor 1996: 3,056
Coppa A, Mincione G, Mammarella S, Ranieri A, Colletta G. Epithelial rat thyroid cell clones, escaping from transforming
growth factor beta negative growth control, are still inhibited by this factor in the ability to trap iodide. Cell Growth Differ.
1995 Mar;6(3):281-90 PMID: 7794796.
[WOS] Journal Impact Factor 1995: 4,179
Vajro P, Fontanella A, De Vincenzo A, Lettera P, Greco L, Coppa A, D'Armiento M. Monitoring of serum alpha-fetoprotein
levels in children with chronic hepatitis B virus infection. J Pediatr Gastroenterol Nutr. 1991 Jan;12(1):27-32
[WOS] Journal Impact Factor 1991: 1.294
Di Carlo A, Mariano A, Coppa A, Macchia V, Maiuri F, Iaconetta G, D'Andrea F. Epidermal growth factor receptor and
tissue tumor markers in human intracranial neoplasms. J Neurosurg Sci. 1990 Jul-Dec;34(3-4):181-5, ISSN 00264881.
[WOS] Journal Impact Factor 1990: 2.87
La Montagna G, Coppa A, Bencivenga T, Tirri G. Serum gastrin, fasting and after stimulation, in systemic sclerosis. Scand
J Rheumatol. 1989;18(5):329-31 doi10.3109/03009748909095038, ISSN 03009742.
[WOS] Journal Impact Factor 1989: 0.855
Macchia V, Mariano A, Cavalcanti M, Coppa A, Cecere C, Fraioli G, Elia S, Ferrante G. Tumor markers and lung cancer:
correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin. Int J Biol Markers.
1987 Sep-Dec;2(3):151-6 doi 10.1177/172460088700200303, ISSN 03936155.
[WOS] Journal Impact Factor 1987: 2.87
Roma, 18-3-2021 Anna Coppa